Since CD126 is expressed on both CD4+CD25- conventional T cells as well as on Tregs (49), tocilizumab could act on both cell types and it was recently shown that tocilizumab treatment also affects the transcriptional signature of Tregs in COVID-19 patients (50). This evidence concerns the gene IL2RA and COVID-19.